Literature DB >> 8721556

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.

H Jacobsen1, M Haenggi, M Ott, I B Duncan, M Andreoni, S Vella, J Mous.   

Abstract

A genotypic analysis of the HIV-1 proteinase was performed on clinical specimen obtained from patients after different periods of Saquinavir (SQV) treatment. Proteinase genes of integrated proviral DNA from PBMC were isolated by PCR, cloned and individual sequences were obtained. Genotypic resistance was defined by the Gly48-->Val and Leu90-->Met exchanges. Frequencies and kinetics of resistance development will be reported for phase I/II trials V13330. V13329, O13328 and ACTG229 in patients on monotherapy or combination therapy with RT inhibitors. Data from V13330 have been analysed in more detail for correspondence of genotypic and phenotypic resistance and any correlation between resistance and changes in plasma viral RNA load. Furthermore, we will discuss the data from our extensive proteinase gene sequence collection with respect to mutational changes which would be indicative of resistance to other inhibitors of HIV-1 proteinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721556     DOI: 10.1016/0166-3542(95)00927-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 2.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

Review 3.  Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Authors:  Babafemi Taiwo; Robert L Murphy; Christine Katlama
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 4.  Current knowledge and future prospects for the use of HIV protease inhibitors.

Authors:  G Moyle; B Gazzard
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Authors:  A Carrillo; K D Stewart; H L Sham; D W Norbeck; W E Kohlbrenner; J M Leonard; D J Kempf; A Molla
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 6.  Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.

Authors:  S Noble; D Faulds
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

7.  Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process.

Authors:  Catherine S Adamson
Journal:  Mol Biol Int       Date:  2012-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.